Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials

By afschroeder • September 22, 2025

Gold LS, Armstrong AW, Bissonnette R, Magnolo N, Vender RB, Sebastian M, Galimberti ML, Tsianakas A, Arnone M, Wallace P, Simon M, Riera-Monroig J, Gerdes S, Waibel J, Gonzalez-Cantero A, Schwarz B, Tada Y, Cecchini M, Ehst B, Kircik L, Kephart L, Reyes-Servin O, Edem BE, Campbell JH, Shen YK, Cresswell K, Li S, DeKlotz CMC, Nunes F, Papp KA. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025 Sep 18:S0140-6736(25)01576-4. doi: 10.1016/S0140-6736(25)01576-4. Epub ahead of print. PMID: 40976249.

Tags: Dermatology, Publications

AlphaFold-driven structural proteomics reveals extensive cellulosome machinery in human ruminococcal symbionts

Minor C, Takayesu A, Arbing MA, Ha SM, Gunsalus RP, Pellegrini M, Sawaya MR, Clubb RT. AlphaFold-driven structural proteomics reveals extensive cellulosome machinery in human[...]

Unraveling the autoimmune architecture of pemphigus: from B-cell depletion to network-based immune engineering

Shafiei-Jahani P, Li X, Akbari A, Vera A, Haniff E, Carlisle R, Akbari O, Holland V. Unraveling the autoimmune architecture of pemphigus: from B-cell depletion[...]

Cerebriform Ridges on the Scalp Signaling a Tumor in the Brain

Park A, Kenney S, Kellogg C, Castillo JR, Bergheim T. Cerebriform Ridges on the Scalp Signaling a Tumor in the Brain. Perm J. 2026 Jul[...]